Target intelligence / Profile preview

Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 capsular polysaccharide (MenW CPS))

Target: MenW-135 capsular polysaccharide (MenW CPS)
Molecular classification: Other (bacterial capsular polysaccharide; carbohydrate antigen)

Overview

The Neisseria meningitidis serogroup W-135 capsular polysaccharide is a surface-expressed carbohydrate capsule that is a principal virulence factor and major antigen defining the W-135 serogroup of N. meningitidis. It consists of alternating residues of sialic acid (N-acetylneuraminic acid) and D-galactose with α-(2→6) and α-(1→4) linkages; it is related to serogroup Y (which alternates sialic acid with D-glucose) but differs in sugar composition and O-acetylation pattern. The capsule protects meningococci against complement-mediated bactericidal activity and opsonization, facilitating bloodstream invasion and meningitis; antibodies to the capsular polysaccharide confer protective immunity. MenW-135 capsule is a component antigen in quadrivalent conjugate vaccines (ACWY), where conjugation to protein carriers enhances immunogenicity and induces functional bactericidal antibodies.

Other names: Neisseria meningitidis group W-135 capsuleMenW capsular polysaccharideW-135 capsular polysaccharide (W-135 CPS)Group W polysaccharide antigen

Mechanism of action

Vaccines: Induction of bactericidal anti-polysaccharide antibodies against MenW-135 capsule when the polysaccharide is conjugated to a protein carrier, enabling T cell–dependent responses and serum bactericidal activity

Biological functions

Immune evasion via complement resistance and anti-opsonic protectionMajor surface antigen determining serogroup identity

Disease associations

Infection (meningococcal meningitis and septicemia caused by N. meningitidis serogroup W-135)

Safety considerations

Polysaccharide antigens can display conformational and O-acetyl–dependent epitopes; antigenic variability (e.g., degree of O-acetylation) may influence immune recognition and assay readoutsManufacturing considerations for identity and O-acetyl content monitoring in vaccine polysaccharides (analytical control is important for consistent immunogenicity)

Interacting drugs

Meningococcal conjugate vaccines containing MenW-135 polysaccharide (e.g., quadrivalent ACWY conjugate vaccines that include the W-135 polysaccharide component conjugated to carrier proteins such as tetanus toxoid)

Biomarkers

Serum bactericidal antibody (SBA) titers against MenW-135 capsule as a correlate of protection after vaccination

Beyond the preview

Go deeper on Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 capsular polysaccharide (MenW CPS)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis serogroup W-135 capsular polysaccharide (MenW-135 capsular polysaccharide (MenW CPS)).

Explore the full profile